Abstract
Background: The forskolin-induced swelling (FIS) assay measures CFTR function on patient-derived intestinal organoids (PDIOs) and may guide treatment selection for individuals with Cystic Fibrosis (CF). The aim of this study is to demonstrate the repeatability and reproducibility of the FIS assay following a detailed Standard Operating Procedure (SOP), thus advancing the validation of the assay for precision medicine (theranostic) applications. Methods: Over a 2-year period, FIS responses to CFTR modulators were measured in four European labs. PDIOs from six subjects with CF carrying different CFTR genotypes were used to assess the repeatability and reproducibility across the dynamic range of the assay. Results: Technical, intra-assay repeatability was high (Lin's concordance correlation coefficient (CCC) 0.95–0.98). Experimental, within-subject repeatability was also high within each lab (CCCs all >0.9). Longer-term repeatability (>1 year) showed more variability (CCCs from 0.67 to 0.95). The reproducibility between labs was also high (CCC ranging from 0.92 to 0.97). Exploratory analysis also found that between-lab percentage of agreement of dichotomized CFTR modulator outcomes for predefined FIS thresholds ranged between 78 and 100 %. Conclusions: The observed repeatability and reproducibility of the FIS assay within and across different labs is high and support the use of FIS as biomarker of CFTR function in the presence or absence of CFTR modulators.
Original language | English |
---|---|
Pages (from-to) | 693-702 |
Number of pages | 10 |
Journal | Journal of Cystic Fibrosis |
Volume | 23 |
Issue number | 4 |
Early online date | 14 May 2024 |
DOIs | |
Publication status | Published - Jul 2024 |
Keywords
- Cystic fibrosis
- Forskolin-induced swelling assay
- Patient-derived intestinal organoids
- Precision medicine
- Repeatability
- Reproducibility